메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background and Objectives:Tuberculous cervical lymphadenitis is one of the most common extrapulmonary manifestations of tuberculosis. Foreign guidelines recommend a six-month short course chemotherapy for tuberculous peripheral lymphadenitis as an initial standard regimen. However, there have been some debates about the duration of chemotherapy in South Korea. The aim of this study is to determine the reasonable duration of chemotherapy for tuberculous cervical lymphadenitis in a randomized controlled study. Subjects and Method:We analyzed clinical outcome of 80 patients with tuberculous cervical lymphadenitis treated at Korea University Medical Center from April 1998 to November 2001. All patients were randomized in two groups by treatment regimens. All patients were given antituberculous chemotherapy for 6 or 12 months, starting with isoniazid (H), rifampicin (R), ethambutol (E) and pyrazinamide (P) for 2 months, then continuing with isoniazid, rifampicin and ethambutol for the remaining 4 months or 10 months, respectively. Results:Forty-seven patients were given a 12-month regimen (2 HERZ/10 HRE), and 43 patients (91.5%) were cured. Thirty-three patients were given a 6-month regimen (2 HERZ/ 4 HRE), and 20 patients (60.6%) were cured. The cure rate of the 12-month regimen appeared significantly higher than that of the 6-month. In both groups, no recurrence was found during the follow up period up to 12 months. Conclusion:The 12-month regimen could be recommended as a reasonable chemotherapy regimen for tuberculous cervical lymphadenitis in South Korea. Single lymph node excisional biopsy is an important diagnostic method. but, it has no additional benefits of treatment.

목차

등록된 정보가 없습니다.

참고문헌 (13)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0